167 related articles for article (PubMed ID: 37273750)
21. Response to toripalimab combined with radiotherapy in advanced non-small cell lung cancer-not otherwise specified: A case report.
Jin Y; Xiao W; Wang X; Cui Y; Li B; Liu X
Medicine (Baltimore); 2021 Oct; 100(42):e27581. PubMed ID: 34678907
[TBL] [Abstract][Full Text] [Related]
22. Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer.
Gao X; Peng L; Zhang L; Huang K; Yi C; Li B; Meng X; Li J
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2661-2671. PubMed ID: 34748028
[TBL] [Abstract][Full Text] [Related]
23. The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study.
Zheng HR; Jiang AM; Gao H; Liu N; Zheng XQ; Fu X; Ruan ZP; Tian T; Liang X; Yao Y
Front Oncol; 2022; 12():894835. PubMed ID: 36203439
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
Zhang S; Li S; Cheng Y
Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504
[TBL] [Abstract][Full Text] [Related]
25. The Efficacy and Safety of Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study.
Zheng HR; Jiang AM; Gao H; Liu N; Zheng XQ; Fu X; Zhang R; Ruan ZP; Tian T; Liang X; Yao Y
Cancer Manag Res; 2022; 14():2273-2287. PubMed ID: 35942069
[TBL] [Abstract][Full Text] [Related]
26. Durvalumab: A Review in Extensive-Stage SCLC.
Al-Salama ZT
Target Oncol; 2021 Nov; 16(6):857-864. PubMed ID: 34731446
[TBL] [Abstract][Full Text] [Related]
27. Durvalumab monotherapy as a third-line treatment for extensive-stage small-cell lung cancer: a case report.
Zhou Q; Zhao J; Wang J; Bao G; Gong LY
Ann Palliat Med; 2020 Jul; 9(4):2386-2392. PubMed ID: 32692233
[TBL] [Abstract][Full Text] [Related]
28. Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report.
Chen SC; Ma DH; Zhong JJ
World J Clin Cases; 2023 Sep; 11(27):6579-6586. PubMed ID: 37900244
[TBL] [Abstract][Full Text] [Related]
29. Real-world eligibility for platinum doublet plus immune checkpoint inhibitors in extensive-stage small-cell lung cancer.
Rittberg R; Leung B; Al-Hashami Z; Ho C
Front Oncol; 2022; 12():1002385. PubMed ID: 36185266
[TBL] [Abstract][Full Text] [Related]
30. Pretreatment prognostic nutritional index is a prognostic marker for extensive-stage small cell lung cancer patients treated with anlotinib.
Liu J; Li S; Zhang S; Yang C; Zhang L; Zhang B; Cheng Y; Wang C
J Thorac Dis; 2020 Oct; 12(10):5765-5773. PubMed ID: 33209408
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non-Small-Cell Lung Cancer After Previous Systemic Treatment Failure-A Retrospective Study.
Wang P; Fang X; Yin T; Tian H; Yu J; Teng F
Front Oncol; 2021; 11():628124. PubMed ID: 33791214
[TBL] [Abstract][Full Text] [Related]
32. Successful Treatment of an Elderly Patient With Combined Small Cell Lung Cancer Receiving Anlotinib: A Case Report.
Gan Y; Liu P; Luo T
Front Oncol; 2021; 11():775201. PubMed ID: 34858856
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study.
Morimoto K; Yamada T; Takeda T; Shiotsu S; Date K; Harada T; Tamiya N; Chihara Y; Hiranuma O; Yamada T; Kanda H; Nakano T; Morimoto Y; Iwasaku M; Tokuda S; Takayama K
JTO Clin Res Rep; 2022 Jul; 3(7):100353. PubMed ID: 35789793
[TBL] [Abstract][Full Text] [Related]
34. Maintenance anlotinib improves the survival prognosis of extensive-stage small cell lung cancer: a single-arm, prospective, phase II study.
Kong F; Wang Z; Wang N; Zhang D; Liao D; Zhang J; Sun Y; Zhang H; Jia Y
Am J Cancer Res; 2023; 13(8):3679-3685. PubMed ID: 37693149
[TBL] [Abstract][Full Text] [Related]
35. Current status and future perspectives of immune checkpoint inhibitors in extensive-stage small cell lung cancer.
Liu X; Xing H; Liu B
Am J Cancer Res; 2022; 12(6):2447-2464. PubMed ID: 35812062
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy versus standard chemotherapy for treatment of extensive-stage small-cell lung cancer: a systematic review.
Liu X; Xing H; Zhang H; Liu H; Chen J
Immunotherapy; 2021 Aug; 13(12):989-1000. PubMed ID: 34114477
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib.
Chen D; Xu J; Zhao Y; Chu T; Zhong H; Han B; Zhong R
J Cancer Res Clin Oncol; 2020 Feb; 146(2):401-406. PubMed ID: 31691871
[TBL] [Abstract][Full Text] [Related]
38. Response to first-line treatment predicts progression-free survival benefit of small-cell lung cancer patients treated with anlotinib.
Qin B; Xin L; Hou Q; Yang B; Zhang J; Qi X; Wei Y; Hu Y; Xiong Q
Cancer Med; 2021 Jun; 10(12):3896-3904. PubMed ID: 33960145
[TBL] [Abstract][Full Text] [Related]
39. The surge of HBsAb level in a HBsAg-negative ES-SCLC patient after anlotinib plus atezolizumab treatment: A case report.
Chen G; Tian T; Cai X
Front Oncol; 2023; 13():1103512. PubMed ID: 37143951
[TBL] [Abstract][Full Text] [Related]
40. Cost-Effectiveness Analysis of Anlotinib as Third- or Further-Line Treatment for Relapsed Small Cell Lung Cancer (SCLC) in China.
Gong J; Wan Q; Shang J; Qian X; Su D; Sun Z; Liu G
Adv Ther; 2021 Oct; 38(10):5116-5126. PubMed ID: 34417989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
